Does Blue Cross Blue Shield of Michigan Cover Novolog?

What Is Novolog and Why Does Formulary Placement Matter?

Novolog is a rapid-acting insulin analog indicated for the treatment of type 1 and type 2 diabetes in adults and pediatric patients aged 2 years and older. The FDA approved it on June 7, 2000 under NDA 020986 [1]. It begins working within 10 to 20 minutes of subcutaneous injection, peaks at 1 to 3 hours, and its effect lasts approximately 3 to 5 hours, making it suitable for mealtime dosing.

Formulary placement determines what you pay. Insulin is classified as an essential health benefit under the Affordable Care Act, but insurers retain the right to place specific insulin products on different tiers [2]. A Tier 2 placement typically means a preferred brand copay, while a Tier 3 placement means a higher non-preferred brand copay. The difference can be $30 to $100 per fill on commercial plans.

How Rapid-Acting Insulins Are Classified

The American Diabetes Association's 2024 Standards of Care categorize rapid-acting insulin analogs as the preferred mealtime insulin class for most people with type 1 diabetes [3]. Novolog competes on BCBS Michigan formularies with Humalog (insulin lispro), Apidra (insulin glulisine), and biosimilars such as Admelog.

Why BCBS Michigan Plans Differ From Each Other

Blue Cross Blue Shield of Michigan offers multiple distinct product lines: Blue Cross commercial PPO, Blue Care Network (HMO), Medicare Advantage, and Medicaid managed care through Blue Cross Complete. Each product maintains its own formulary. A member on a Blue Care Network HMO plan may find Novolog on Tier 3 while a member on a Blue Cross PPO plan finds it on Tier 2.

Novolog's Typical Tier Placement on BCBS Michigan Plans

On most 2024 and 2025 BCBS Michigan commercial formularies, Novolog sits at Tier 2 (preferred brand) or Tier 3 (non-preferred brand), depending on the specific plan design your employer selected. Tier 2 copays for commercial members generally run $40 to $60 per 30-day supply. Tier 3 copays can reach $80 to $120 before meeting a deductible.

Blue Care Network Formulary

Blue Care Network's 2025 Value Formulary lists insulin aspart products in the insulin analogs, rapid-acting category. Members should download the current BCN drug list at bcbsm.com or call 1-800-637-2227 to confirm the current tier for their specific plan, because employer-sponsored plans can negotiate custom formulary exceptions.

Medicare Part D and the $35 Insulin Cap

Medicare Part D plans sold by BCBS Michigan are subject to the Inflation Reduction Act of 2022, which capped cost-sharing on covered insulin products at $35 per month per covered insulin starting January 1, 2023 [4]. Novolog is covered under most BCBS Medicare Part D formularies, and the $35 cap applies regardless of whether the member has met their deductible. The Centers for Medicare and Medicaid Services confirmed this benefit applies to all Part D-covered insulins [4].

Medicaid (Blue Cross Complete)

Michigan Medicaid covers insulin under the Michigan Department of Health and Human Services Preferred Drug List. Insulin aspart (Novolog) is listed as a covered drug with no prior authorization required for Medicaid beneficiaries in most circumstances [5]. Cost-sharing for Medicaid members is minimal, typically $1 to $3 per prescription.

Prior Authorization Requirements for Novolog

Prior authorization (PA) is a process where your insurance plan requires your prescriber to demonstrate medical necessity before covering a specific drug. BCBS Michigan requires PA for Novolog on select commercial plan designs, particularly those with step therapy protocols.

When Is Prior Authorization Triggered?

PA is most commonly required when:

• Novolog is placed on Tier 3 and the plan has a step therapy requirement to try a Tier 2 rapid-acting insulin first
• The prescription is for a non-standard formulation (such as Novolog 200 units/mL PenFill cartridges)
• The quantity requested exceeds the plan's default supply limit

What Your Prescriber Needs to Submit

Your endocrinologist or primary care physician must typically submit clinical documentation including your diabetes diagnosis code (ICD-10 E10.x for type 1 or E11.x for type 2), any contraindications or adverse reactions to alternative insulins, and HbA1c values. The American Diabetes Association advises that "insulin analogs, when prescribed appropriately, reduce hypoglycemia risk compared to human insulin formulations" [3], language that prescribers can cite in PA letters when step therapy protocols require a medical exception.

Typical PA Timeline

BCBS Michigan is required under Michigan insurance law to respond to standard PA requests within 14 days and urgent PA requests within 72 hours. If you are already on Novolog and switching plans, ask your prescriber to submit a PA request with a continuity-of-care argument the day you enroll.

Step Therapy and Alternatives BCBS Michigan May Require First

Step therapy (sometimes called fail-first) means the plan requires you to try and fail on a lower-tier drug before it will cover the higher-tier drug. For rapid-acting insulins, BCBS Michigan step therapy protocols on some commercial plans require a trial of a preferred Tier 2 analog such as Humalog before covering Novolog.

Clinical Equivalence Between Rapid-Acting Analogs

A 2021 meta-analysis published in Diabetes Care (N=4,462 subjects across 18 randomized trials) found no statistically significant difference in HbA1c reduction between insulin aspart and insulin lispro, with a mean HbA1c difference of 0.01% (95% CI: -0.08 to 0.10) [6]. This equivalence data means that from a pure glycemic standpoint, step therapy to Humalog is clinically defensible, though individual tolerability, injection device preference, and established glycemic control on Novolog are all valid medical reasons to seek an exception.

Requesting a Step Therapy Exception

Michigan's Step Therapy Act (Public Act 352 of 2018) gives patients the right to request a step therapy override if:

1. The required alternative is contraindicated
2. The patient previously tried and failed the alternative
3. The patient is currently stable on Novolog and a switch could cause clinical harm

Your prescriber submits a step therapy exception request alongside a PA. BCBS Michigan must respond within 72 hours for urgent cases.

How Much Does Novolog Cost With BCBS Michigan Coverage?

Out-of-pocket costs depend on your plan's deductible, tier, and copay structure. Here is a realistic breakdown for a 10 mL vial of Novolog (100 units/mL):

| Plan Type | Formulary Tier | Estimated Member Cost | |---|---|---| | Commercial PPO (Tier 2) | Preferred brand | $40, $60 per vial | | Commercial PPO (Tier 3) | Non-preferred brand | $80, $120 per vial | | Blue Care Network HMO | Varies by plan | $35, $75 per vial | | Medicare Part D | Any covered tier | $35/month cap (IRA 2022) | | Medicaid (Blue Cross Complete) | PDL covered | $1, $3 per fill |

These figures apply after you have met your deductible. Before the deductible is satisfied, you pay the full negotiated price, which BCBS Michigan has typically negotiated to $150 to $250 per vial for Novolog (substantially below the $289 retail list price as of 2024 [7]).

The Novo Nordisk $99 Per Month Cap

Novo Nordisk launched its My99Insulin program in January 2021, capping out-of-pocket costs at $99 per month for all Novo Nordisk insulin products, including Novolog, regardless of insurance status. Patients who pay more than $99 per month under their insurance plan can use this program directly at the pharmacy [8]. This is distinct from the manufacturer copay card, which is available only to commercially insured patients.

The Novo Nordisk Copay Card

Commercially insured patients (not Medicare or Medicaid) may use the Novo Nordisk NovoCare copay card to pay as little as $25 per month for Novolog. The card is available at novocare.com and can be activated in minutes. It cannot be used with government-funded insurance programs.

What to Do If BCBS Michigan Denies Novolog Coverage

A denial is not final. Federal law and Michigan state law give you defined appeal rights, and many PA denials are overturned on appeal when supported by documentation.

Step 1: Request a Written Denial Notice

BCBS Michigan must provide a written explanation of the denial, including the specific formulary or clinical criteria not met. Ask for this in writing if you received a verbal denial.

Step 2: File an Internal Appeal

You have 180 days from the denial date to file an internal appeal with BCBS Michigan. Submit your appeal with:

• A letter of medical necessity from your prescriber
• Relevant lab values (HbA1c, fasting glucose logs)
• Documentation of any adverse reactions to alternative insulins
• The ADA 2024 Standards of Care section supporting insulin analog use [3]

Step 3: Request External Review

If the internal appeal is denied, you may request an independent external review through the Michigan Department of Insurance and Financial Services (DIFS). Under the ACA, external review decisions are binding on the insurer. External reviewers overturn insurance denials approximately 40% of the time according to a 2022 JAMA Internal Medicine study of commercial insurance external reviews [9].

Step 4: Use Manufacturer Assistance While Appealing

Do not wait without insulin while an appeal is pending. Activate the Novo Nordisk My99Insulin program or NovoCare Patient Assistance Program (for uninsured or underinsured patients below 400% of the federal poverty level) to maintain your supply during the appeals process [8].

Biosimilar Insulins as Covered Alternatives

The FDA has approved several biosimilar and interchangeable insulin products that may be on a lower BCBS Michigan formulary tier than Novolog:

• Admelog (insulin lispro-aabc): FDA-approved December 2017 [10], rapid-acting, often on Tier 2
• Lyumjev (insulin lispro-aabc, ultra-rapid): FDA-approved June 2020 [11], faster onset than Novolog
• Fiasp (faster insulin aspart): FDA-approved September 2017 [12], a reformulation of insulin aspart with 5 minutes faster onset

A 2020 randomized crossover trial published in Diabetes Care (N=236) found Fiasp reduced postprandial glucose excursions by 1.8 mmol/L more than standard Novolog at 1 hour post-meal [13]. If your BCBS Michigan plan covers Fiasp at a lower tier, and your provider agrees it is clinically appropriate, it could reduce your costs without sacrificing glycemic control.

The HealthRX Insulin Coverage Decision Framework: When evaluating whether to accept a formulary alternative or appeal for Novolog specifically, consider three factors in order: (1) whether you have established stable glycemic control on Novolog (HbA1c at goal with current device), (2) whether the proposed alternative uses a compatible injection device with your current routine, and (3) whether the net monthly cost difference after applying all manufacturer assistance programs exceeds $50. If all three factors favor the alternative, a therapeutic switch is reasonable. If any factor raises a clinical concern, a PA appeal with prescriber documentation is warranted.

Novolog Dosing and Clinical Background

Novolog is FDA-approved for subcutaneous injection, continuous subcutaneous infusion via insulin pump, and intravenous use in clinical settings [1]. The standard subcutaneous dose is individualized based on body weight, carbohydrate intake, and insulin sensitivity. General starting doses in type 2 diabetes range from 4 units per meal, titrated upward based on pre-meal glucose targets.

Clinical Trial Evidence Supporting Novolog

The PREDICTIVE 303 trial (N=5,604) demonstrated that insulin aspart used in a self-adjustment algorithm reduced hypoglycemic events while maintaining HbA1c at 7.4% over 26 weeks in a real-world type 2 diabetes population [14]. The FDA's prescribing information notes a mean HbA1c reduction of 0.7% versus NPH insulin in type 1 diabetes patients over 24 weeks in the key trial supporting approval [1].

Safety Considerations

Novolog carries a class warning for hypoglycemia, the most common adverse effect of insulin therapy. The FDA's 2023 insulin class labeling update reinforced that all rapid-acting analogs require individualized dosing and patient education on hypoglycemia recognition and treatment [15]. The ADA recommends a target HbA1c of <7% for most non-pregnant adults with diabetes, with less stringent targets (7.5 to 8%) appropriate for patients with hypoglycemia unawareness or limited life expectancy [3].

Verifying Your Specific BCBS Michigan Plan's Coverage

Coverage details change annually during open enrollment. Always verify Novolog's current tier status by:

1. Logging into your BCBS Michigan member account at bcbsm.com and using the drug lookup tool
2. Calling member services at 1-800-637-2227 and asking specifically for your plan's formulary tier, PA requirements, and quantity limits for NDC 00169-7501-11 (Novolog 10 mL vial, 100 units/mL)
3. Asking your pharmacy to run a test claim before you pick up the prescription, which shows your exact out-of-pocket cost under your current benefits

Annual formulary changes take effect January 1, and BCBS Michigan is required to notify members of tier changes for drugs they are actively using at least 60 days before the change takes effect under CMS regulations for Medicare plans and Michigan insurance law for commercial plans.